A new class of compound for pancreatic carcinoma targeting the tyrosine kinase receptor (TKR) ROR1.
Håkan Mellstedt(Karolinska University Hospital), Anders Österborg(Karolinska University Hospital), Eva Mikaelsson(Karolinska University Hospital), Thomas Olin(Kancera (Sweden)), Ali Moshfegh(Karolinska University Hospital), Amir Hossein Daneshmanesh(Karolinska University Hospital), Mohammad Hojjat‐Farsangi(Karolinska University Hospital), Jan Vågberg(Kancera (Sweden)), Johan Schultz(Kancera (Sweden)), Styrbjörn Byström(Karolinska Institutet), Salam Khan
Cited by 5
Related Papers
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2010|587
Nanoparticles and targeted drug delivery in cancer therapy
|Immunology Letters|2017|507
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2022|453
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer
|Biomedicine & Pharmacotherapy|2018|312